Hikma Pharmaceuticals (OTCMKTS:HKMPF) Reaches New 12-Month High – What’s Next?

Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF)’s stock price reached a new 52-week high during trading on Monday . The company traded as high as $28.92 and last traded at $28.92, with a volume of 8632 shares trading hands. The stock had previously closed at $28.14.

Analyst Ratings Changes

Separately, Royal Bank of Canada raised shares of Hikma Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Tuesday, December 10th.

Hikma Pharmaceuticals Stock Up 2.7 %

The company has a quick ratio of 0.98, a current ratio of 1.66 and a debt-to-equity ratio of 0.46. The business’s fifty day moving average is $25.71 and its two-hundred day moving average is $25.29.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.